Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.
17 Julho 2023 - 6:02PM
Business Wire
Priveterra Acquisition Corp. (Nasdaq: PMGM) (“Priveterra” and,
after the consummation of its pending business combination (the
“Business Combination”) and following its name change to AEON
Biopharma, Inc., “New AEON”) today announced that NYSE Regulation,
on July 13, 2023, authorized New AEON common stock (“New AEON
Common Stock”) and New AEON warrants to be listed on NYSE American
LLC (“NYSE”) upon the Business Combination with AEON Biopharma,
Inc., (“AEON”) following which AEON will be a wholly owned
subsidiary of Priveterra and Priveterra will change its name to
AEON Biopharma, Inc.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230717921274/en/
Trading is expected to begin on NYSE on July 24, 2023, under the
new ticker symbol “AEON” for the New AEON Common Stock following
the consummation of the Business Combination, which is expected to
occur on July 21, 2023, subject to satisfaction or waiver of
standard, customary closing conditions.
As of July 17, 2023, Priveterra’s public stockholders holding
1,681,348 shares, out of a total of 2,002,272 shares, of Class A
common stock validly elected to redeem their public shares for a
full pro rata portion of the trust account holding the proceeds
from Priveterra’s initial public offering, leaving 320,924 shares
remaining. The redemption price as of July 17, 2023 is
approximately $10.62.
Priveterra will be automatically accepting requests by
stockholders to withdraw their previously submitted redemption
requests until 5:00 p.m. Eastern Time on July 20, 2023.
No action is required by existing PMGM shareholders with respect
to the ticker symbol or exchange listing change.
About Priveterra Acquisition Corp.
Priveterra Acquisition Corp. (NASDAQ: PMGM) is a blank-check
company formed for the purpose of effecting a merger, share
exchange, asset acquisition, share purchase, reorganization, or
similar business combination with one or more businesses in life
sciences. Priveterra is sponsored by Robert Palmisano and
Priveterra Capital, LLC.
Forward-Looking Statements
This Current Report on Form 8-K includes “forward-looking
statements” within the meaning of the safe harbor provisions of the
United States Private Securities Litigation Reform Act of 1995.
Forward-looking statements generally relate to future events
involving, or future performance of, the Company or AEON. In some
cases, you can identify forward-looking statements by terminology
such as “pro forma”, “may”, “should”, “could”, “might”, “plan”,
“possible”, “project”, “strive”, “budget”, “forecast”, “expect”,
“intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”,
“potential” or “continue”, or the negatives of these terms or
variations of them or similar terminology. Such forward-looking
statements are subject to risks, uncertainties, and other factors
which could cause actual results to differ materially from those
expressed or implied by such forward-looking statements. These
forward-looking statements are based upon estimates and assumptions
that, while considered reasonable by the Company and its
management, and AEON and its management, as the case may be, are
inherently uncertain. Certain risks and uncertainties are set forth
in the section entitled “Risk Factors” and “Cautionary Note
Regarding Forward-Looking Statements” in the Company’s final
prospectus dated February 11, 2021, relating to its IPO and other
risks and uncertainties indicated from time to time in the
definitive proxy statement to be delivered to the Company’s
stockholders and related S-4 Registration Statement, including
those set forth under “Risk Factors” therein, and other documents
filed to be filed with the SEC by the Company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230717921274/en/
Investor Contact: Priveterra Acquisition Corp.
spac@priveterra.com
Priveterra Acquisition C... (NASDAQ:PMGM)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Priveterra Acquisition C... (NASDAQ:PMGM)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024